Su1875: IMPACT OF OZANIMOD (OZA) ON CIRCULATING NEUTROPHILS: RESULTS FROM THE PHASE 3 JAPANESE TRUE NORTH (J-TN) STUDY OF PATIENTS (PTS) WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC)

Article2023

Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study

Laurent Peyrin‐Biroulet, Jessica R. Allegretti, David T. Rubin, Brian Bressler, Matthew Germinaro, Kuan‐Hsiang Gary Huang, Nicole Shipitofsky, Hongyan Zhang, Rebbecca Wilson, Chenglong Han, Brian G. Feagan, William J. Sandborn, Julián Panés, Tadakazu Hisamatsu, Gary R. Lichtenstein, Bruce E. Sands, Axel Dignaß, О. Аbrahamovych, Halyna Afanasieva, Lilia Aitova, Engin Altıntaş, Romain Altwegg, П. С. Андреев, Kazuki Aomatsu, Monika Augustyn, Paola Balestrieri, Jakob Begun, Luciana Soledad Brunatto, Diego Bulgheroni, Elena Bunkova, Mercedes Cabello, Qian Cao, Flavio Caprioli, Rute Cerqueira, Baili Chen, Chou‐Chen Chen, Chou-Pin Chen, Cheng‐Tang Chiu, Chang Hwan Choi, Michele Cicala, Olena Datsenko, Pieter Dewint, Eugeni Domènech, Joris Dutré, George Duvall, J. C. Fernández, Rafał Filip, Ronald Fogel, Sharyle Fowler, Toshimitsu Fujii, Masayuki Fukata, Yohei Furumoto, Antonio Gasbarrini, Beata Gawdis-Wojnarska, Cyrielle Gilletta, Paolo Gionchetti, Eran Goldin, Oleksandr Golovchenko, Maciej Gonciarz, Can Gönen, Gaston Gonzalez Segura, Oleksii Gridnyev, T Gyökeres, Xavier Hébuterne, Charlotte Hedin, Per M. Hellström, Ida Hilmi, Ivo Horný, Gyula Horvat, Namiko Hoshi, Luděk Hrdlička, Shunji Ishihara, Olha Ivanishyn, Byung Ik Jang, Odery Ramos, Takashi Kagaya, Shuji Kanmura, Marina Karakina, Nakai Katsuhiko, Jarosław Kierkuś, Hyo Jong Kim, Tae Oh Kim, Young‐Ho Kim, G Kiss, Jochen Klaus, D Kleczkowski, Maria Kłopocka, Taku Kobayashi, Iwona Kobielusz‐Gembala, Ja Seol Koo, Adam Kopoń, Tetiana Kravchenko, Masatoshi Kudo, Kwang An Kwon, Paula Lago, David Laharie, Ian C. Lawrance, Jarosław Leszczyszyn, Yan Li, Milan Lukáš

Article2019

P573 Real-world effectiveness and safety of vedolizumab and anti-TNF in biologic-naive ulcerative colitis patients: Results from the EVOLVE study

Andrés Yarur, Gerassimos J. Mantzaris, Mark S. Silverberg, Margaret Walshe, Petros Zezos, Dan Joseph Stein, M Bassel, T Lissoos, Claudia Lopez, Athanasios Natsios, Gabriela Radulescu, Haridarshan Patel, Dirk Demuth, Brian Bressler

Article2024

P-395 Updated Results From DREAMM-3, a Phase 3 Study of Belantamab Mafodotin (Belamaf) Versus Pomalidomide Plus Dexamethasone in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM)

Vânia Hungria, Katja Weisel, Atanas Radinoff, Sosana Delimpasi, Gábor Mikala, Tamás Masszi, Jian Li, Marcelo Capra, Ângelo Maiolino, Vasiliki Pappa, Dominik Chraniuk, Iurii Osipov, Xavier Leleu, Michael Löw, Fotini M. Kouri, John Liboon, Chris Brawley, Eric Lewis, Gabriela Tubel, Mary Li, Astrid McKeown, Sumita Roy–Ghanta,

Article2018

Preliminary results from patients with urothelial carcinoma (UC) in a phase 1A/1B study of bgb-A317, an anti-PD-1 monoclonal antibody.

Shahneen Sandhu, Andrew G. Hill, Hui Gan, Michael Friedlander, Mark Voskoboynik, Paula Barlow, Amanda Townsend, James Song, Yun Zhang, Zhirong Shen, Qinzhou Qi, Jayesh Desai

Article2014

Carfilzomib (K) Vs Low-Dose Corticosteroids and Optional Cyclophosphamide (Cy) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma (Rrmm): Results from a Phase 3 Study (Focus)

Heinz Ludwig, Tamás Masszi, Maria Teresa Petrucci, Antonio Palumbo, Laura Rosiñol, Arnon Nagler, Kwee Yong, Jiří Minařík, Meletios A Dimopoulos, Vladimír Maisnar, Davide Rossi, H. Kasparu, Dina Ben‐Yehuda, Izhar Hardan, Matthew Jenner, Kanya Rajangam, Jesús F. San Miguel, Roman Hájek

Discussion(0)

Related publications